GlassScriptPhysician profile
Leslie Chan
NPI 1912039850
$3,504.64
in general payments reported to CMS, 2019-2025
25 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $68.69 · 2021: $142 · 2022: $143 · 2023: $676 · 2024: $780 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,673.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,070.26 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Abbvie INC. | $418.57 | 2023-2025 | Qulipta, Botox, Ubrelvy |
| Collegium Pharmaceutical, INC. | $280.87 | 2023-2025 | Belbuca, Xtampza |
| Scilex Pharmaceuticals INC. | $273.04 | 2019-2024 | Ztlido |
| Medtronic USA, INC. | $261.00 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $218.72 | 2024-2025 | Relistor |
| Boston Scientific Corporation | $160.44 | 2025 | Intracept |
| Nevro Corp. | $145.60 | 2019-2024 | Senza |
| Spr Therapeutics, INC | $134.27 | 2022-2023 | Sprint Pns System |
| Globus Medical, INC. | $130.88 | 2025 | Senza |
| Averitas Pharma INC. | $44.46 | 2024 | Qutenza |
| Biohaven Pharmaceuticals, INC. | $39.70 | 2021 | |
| Stryker Corporation | $37.29 | 2023-2025 | Mild Device Kit, Spinejack |
| Valinor Pharma, LLC | $34.33 | 2025 | Movantik |
| Pfizer INC. | $31.31 | 2019-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $29.38 | 2025 | |
| Abbott Laboratories | $29.11 | 2023 | Proclaim |
| Saluda Medical Americas, INC. | $29.06 | 2025 | Evoke |
| Zyla Life Sciences, INC. | $28.07 | 2019 | |
| Sentynl Therapeutics, INC. | $27.22 | 2019 | |
| Zimmer Biomet Holdings, INC. | $20.72 | 2025 | Gel-One Cross-Linked Hyaluronate, Visco-3 Sodium Hyaluronate |
| Appliedvr INC | $20.14 | 2025 | Relievrx |
| Allergan, INC. | $15.93 | 2019 | |
| Daiichi Sankyo INC. | $12.96 | 2019 | |
| Biodelivery Sciences International, INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.